Key result
Flaxseed oil lowers systolic blood pressure by ~4 mmHg in metabolic syndrome.
Meta-Analysis
Answers are grounded in this paper and cite their sources.
We systematically reviewed randomized clinical trials (RCTs) to elucidate the overall effects of flaxseed oil consumption on blood pressure (BP) in patients with metabolic syndrome and related disorders. PubMed, Scopus, Cochrane Library, and ISI Web of Science databases were systematically searched until March 31, 2020, to find RCTs that examined the effect of flaxseed oil consumption on BP. Weighed mean difference (WMD) was pooled using a random-effects model. Standard methods were used for the assessment of heterogeneity, sensitivity analysis, and publication bias. Meta-analysis of five trials (6 arms) showed significant reductions in systolic (WMD: -3.86 mmHg, 95% CI: -7.59 to -0.13, p = .04) BP (SBP) after flaxseed oil consumption. However, the overall effect illustrated no significant change in diastolic (WMD: -1.71 mmHg, 95% CI: -3.67 to 0.26, p = .09) BP (DBP) in the intervention group compared with the control group. Our findings revealed that flaxseed oil consumption has favorable effects on SBP in patients with metabolic syndrome and related disorders. However, further investigations are needed to provide more reliable evidence.
No takes yet. Share an insight, caveat, or question.
Mahmudiono et al. (2022) conducted a meta-analysis in Metabolic syndrome and related disorders. Flaxseed oil vs. Control was evaluated on Systolic blood pressure (SBP) (WMD -3.86 mmHg, 95% CI -7.59 to -0.13, p=.04). Flaxseed oil consumption significantly reduced systolic blood pressure in patients with metabolic syndrome (WMD -3.86 mmHg; 95% CI -7.59 to -0.13; P=0.04), with no significant effect on diastolic BP.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: